Canada - English - Health Canada

les produits gerbex inc. - zinc (zinc gluconate) - tablet - 50mg - zinc (zinc gluconate) 50mg - minerals

United States - English - NLM (National Library of Medicine)

deseret biologicals, inc. - cholesterol (unii: 97c5t2uq7j) (cholesterol - unii:97c5t2uq7j) - cholesterol 6 [hp_x] in 1 ml - for temporary relief of symptoms related to adrenal glands such as fatigue and low energy.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration. for temporary relief of symptoms related to adrenal glands such as fatigue and low energy.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration.

United States - English - NLM (National Library of Medicine)

ironwood pharmaceuticals, inc. - lesinurad (unii: 09erp08i3w) (lesinurad - unii:09erp08i3w), allopurinol (unii: 63cz7gjn5i) (allopurinol - unii:63cz7gjn5i) - lesinurad 200 mg - duzallo®, a combination of lesinurad, a uric acid transporter 1 (urat1) inhibitor, and allopurinol, a xanthine oxidase inhibitor, is indicated for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a medically appropriate daily dose of allopurinol alone [see clinical studies (14) ]. duzallo is not recommended for the treatment of asymptomatic hyperuricemia. the use of duzallo is contraindicated in the following conditions: - severe renal impairment (eclcr less than 30 ml/min), end-stage renal disease, kidney transplant recipients, or patients on dialysis [see use in specific populations (8.6) ]. - tumor lysis syndrome or lesch-nyhan syndrome [see use in specific populations (8.8) ]. - known hypersensitivity to allopurinol, including previous occurrence of skin rash [see warnings and precautions (5.2) ]. risk summary there are no available human data on use of duzallo or lesinurad in pregnant women to inform a drug-associated risk of adverse

United States - English - NLM (National Library of Medicine)

ironwood pharmaceuticals, inc. - lesinurad (unii: 09erp08i3w) (lesinurad - unii:09erp08i3w) - lesinurad 200 mg - zurampic is indicated in combination with a xanthine oxidase inhibitor for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone [see clinical studies (14) ]. zurampic is not recommended for the treatment of asymptomatic hyperuricemia. zurampic should not be used as monotherapy [see warnings and precautions (5.1) ]. the use of zurampic is contraindicated in the following conditions: - severe renal impairment (eclcr less than 30 ml/min), end stage renal disease, kidney transplant recipients, or patients on dialysis [see use in specific populations (8.6) ] - tumor lysis syndrome or lesch-nyhan syndrome [see use in specific populations (8.8) ]. risk summary there are no available human data on use of zurampic in pregnant women to inform a drug-associated risk. no teratogenicity or effects on fetal development were observed in embryo-fetal development studies with oral administration of lesinurad to pregnant rats

Canada - English - Health Canada

les produits de soins pour la peau au lait de chevre canus inc/canus goat's milk - zinc oxide; petrolatum - ointment - 40%; 49.5% - zinc oxide 40%; petrolatum 49.5% - basic ointments and protectants

United States - English - NLM (National Library of Medicine)

canus vermont llc - zinc oxide (unii: soi2loh54z) (zinc oxide - unii:soi2loh54z), petrolatum (unii: 4t6h12bn9u) (petrolatum - unii:4t6h12bn9u) - zinc oxide 40 g in 142 g - skin protectant. helps treat and prevent diaper rash if condition worsens or does not improve within 7 days.

United States - English - NLM (National Library of Medicine)

ohm pharma inc. - cholesterol (unii: 97c5t2uq7j) (cholesterol - unii:97c5t2uq7j), bos taurus bile (unii: et3651zlou) (bos taurus bile - unii:et3651zlou), malmea depressa bark (unii: xa09475c3b) (malmea depressa bark - unii:xa09475c3b) - cholesterol 13 [hp_c] in 59 ml - uses: temporarily relieves ailments related with slow hepatic metabolism resulting in elevated cholesterol levels.** **this statement has not been evaluated by the fda. it is based on documented homeopathic materia medica .

European Union - English - EMA (European Medicines Agency)

ipsen pharma - mecasermin - laron syndrome - pituitary and hypothalamic hormones and analogues - for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like-growth-factor-1 deficiency (primary igfd).severe primary igfd is defined by:height standard deviation score ≤ -3.0 and;basal insulin-like growth factor-1 (igf-1) levels below the 2.5th percentile for age and gender and;growth hormone (gh) sufficiency;exclusion of secondary forms of igf-1 deficiency, such as malnutrition, hypothyroidism, or chronic treatment with pharmacologic doses of anti-inflammatory steroids.severe primary igfd includes patients with mutations in the gh receptor (ghr), post-ghr signalling pathway, and igf-1 gene defects; they are not gh deficient, and therefore, they cannot be expected to respond adequately to exogenous gh treatment. it is recommended to confirm the diagnosis by conducting an igf-1 generation test.

Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - fluconazole - capsules - fluconazole 200 mg - fluconazole - fluconazole - fluconazole is indicated in the following fungal infections.fluconazole is indicated in adults for the treatment of:• cryptococcal meningitis.• coccidioidomycosis.• invasive candidiasis.• mucosal candidiasis including oropharyngeal, oesophageal candidiasis, candiduria and chronic mucocutaneous candidiasis.• chronic oral atrophic candidiasis (denture sore mouth) if dental hygiene or topical treatment are insufficient.• vaginal candidiasis, acute or recurrent; when local therapy is not appropriate.• candidal balanitis when local therapy is not appropriate.• dermatomycosis including tinea pedis, tinea corporis, tinea cruris, tinea versicolor and dermal candida infections when systemic therapy is indicated.• tinea unguinium (onychomycosis) when other agents are not considered appropriate.fluconazole is indicated in adults for the prophylaxis of:• relapse of cryptococcal meningitis in patients with high risk of recurrence.• relapse of oropharyngeal or oesophageal candidiasis in patients infected with hiv who are at high risk of experiencing relapse.• to reduce the incidence of recurrent vaginal candidiasis (4 or more episodes a year).• prophylaxis of candidal infections in patients with prolonged neutropenia (such as patients with haematological malignancies receiving chemotherapy or patients receiving hematopoietic stem cell transplantation).fluconazole is indicated in term newborn infants, infants, toddlers, children, and adolescents aged from 0 to 17 years old:fluconazole is used for the treatment of mucosal candidiasis (oropharyngeal, oesophageal), invasive candidiasis, cryptococcal meningitis and the prophylaxis of candidal infections in immunocompromised patients. fluconazole can be used as maintenance therapy to prevent relapse of cryptococcal meningitis in children with high risk of reoccurrence. therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti infective therapy should be adjusted accordingly.consideration should be given to official guidance on the appropriate use of antifungals.

Israel - English - Ministry of Health

j-c health care ltd - loperamide hydrochloride - capsules - loperamide hydrochloride 2 mg - antipropulsives - control and symptomatic relief of acute diarrhea in adults, adolescents and children aged 6 years and older.